CALC - NASDAQ
CalciMedica, Inc.
$5.12
-1.9%CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
At a Glance
Live Snapshotcalc
Cash at Beginning of Period
Last Annual Value
5.53M
3-Year CAGR
-45%
5-Year CAGR
-15%
10-Year CAGR
27%
CalciMedica, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 CalciMedica, Inc. NASDAQ:CALC | 5.53M | 55.3% | -30.2% | N/A | |
 Xilio Therapeutics, Inc. NASDAQ:XLO | 57.07M | -22.0% | 22.4% | N/A | |
 MAIA Biotechnology, Inc. AMEX:MAIA | 9.60M | -4.3% | 70.6% | N/A | |
 Actinium Pharmaceuticals, Inc. AMEX:ATNM | 76.99M | -11.0% | 3.8% | 11.6% | |
 PDS Biotechnology Corporation NASDAQ:PDSB | 41.69B | 726.6% | 328.6% | 78.1% | |
 Elutia Inc. NASDAQ:ELUT | 13.24M | -8.0% | -19.7% | N/A |
CalciMedica, Inc. Fair Value Envelope
Related Guides
Continue your CALC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.